Literature DB >> 12577161

[Clinical management of patients with sepsis].

M A Weigand1, H J Bardenheuer, B W Böttiger.   

Abstract

Sepsis and septic shock are the leading causes of death in non-cardiological intensive care units in developed countries despite recent advances in critical care medicine. Sepsis is the systemic inflammatory response to infection, often associated with hypoperfusion followed by tissue injury and organ failure. Activation of monocytes/macrophages and neutrophils with consecutive release of proinflammatory mediators and activation of the coagulation cascade, seem to play a key role in the pathogenesis of sepsis. Elimination of the septic focus,antimicrobial therapy and supportive treatment are the cornerstones of sepsis therapy. Adequate and rapid volume replacement and if necessary application of catecholamines are of highest priority to optimize tissue perfusion. Norepinephrine is the vasopressor of choice and dobutamine the preferred inotropic agent. Most experts recommend hemoglobin levels of 8-10 g/dl in severe sepsis. In addition,lung protective ventilatory strategies as well as enteral and parenteral nutrition are part of the clinical management of septic patients. In mechanically ventilated patients intensive insulin therapy to maintain blood glucose at a level between 80 and 110 mg/dl has significantly reduced mortality.Furthermore,prophylaxis of deep vein thrombosis and of stress ulcer bleeding are individually applied to septic patients. Treatment of septic patients with anti-mediator strategies or high dose AT III were not successful so far. In contrast,now two new promising treatment options may be emerging: application of small doses hydrocortisone and activated protein C [drotrecogin alfa (activated)]. Large and in part multicentric studies especially in the last 2 years now allow the practicing clinician to perform a partially evidence-based management of patients with sepsis. In addition, for the first time two options for specific therapy of sepsis,application of small doses hydrocortisone and activated protein C [drotrecogin alfa (activated)],are available which may further improve prognosis for septic patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12577161     DOI: 10.1007/s00101-002-0436-0

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  12 in total

1.  Prospective evaluation of regional oxygen saturation to estimate central venous saturation in sepsis.

Authors:  Christian Koch; Rainer Röhrig; Tobias Monz; Andreas Hecker; Florian Uhle; Emanuel Schneck; Markus A Weigand; Christoph Lichtenstern
Journal:  J Clin Monit Comput       Date:  2015-03-11       Impact factor: 2.502

2.  [Near-infrared spectroscopy in sepsis therapy : predictor of a low central venous oxygen saturation].

Authors:  C Lichtenstern; C Koch; R Röhrig; B Rosengarten; M Henrich; M A Weigand
Journal:  Anaesthesist       Date:  2012-09-27       Impact factor: 1.041

3.  [Non-invasive extended hemodynamic monitoring. Reduction of circulatory risk situations].

Authors:  M Bock; T Sturm; J Motsch
Journal:  Anaesthesist       Date:  2007-07       Impact factor: 1.041

Review 4.  [Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin].

Authors:  M Angstwurm; J Hoffmann; H Ostermann; L Frey; M Spannagl
Journal:  Anaesthesist       Date:  2009-02       Impact factor: 1.041

5.  Redox responses in patients with sepsis: high correlation of thioredoxin-1 and macrophage migration inhibitory factor plasma levels.

Authors:  Thorsten Brenner; Claudia Rosenhagen; Jochen Steppan; Christoph Lichtenstern; Jürgen Weitz; Thomas Bruckner; Eike O Martin; Ursula Hoffmann; Markus A Weigand; Stefan Hofer
Journal:  Mediators Inflamm       Date:  2010-08-05       Impact factor: 4.711

6.  Peritoneal instillation of taurolidine or polihexanide modulates intestinal microcirculation in experimental endotoxemia.

Authors:  Helge Frieling; Kai-Steffen Lauer; Matthias Gründling; Taras Usichenko; Konrad Meissner; Theoni Kanellopoulou; Christian Lehmann; Michael Wendt; Dragan Pavlovic
Journal:  Int J Colorectal Dis       Date:  2006-11-21       Impact factor: 2.796

7.  L-arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure.

Authors:  Thorsten Brenner; Thomas H Fleming; Claudia Rosenhagen; Ute Krauser; Markus Mieth; Thomas Bruckner; Eike Martin; Peter P Nawroth; Markus A Weigand; Angelika Bierhaus; Stefan Hofer
Journal:  Mediators Inflamm       Date:  2012-05-06       Impact factor: 4.711

8.  Reduced serum butyrylcholinesterase activity indicates severe systemic inflammation in critically ill patients.

Authors:  Aleksandar R Zivkovic; Karsten Schmidt; Annette Sigl; Sebastian O Decker; Thorsten Brenner; Stefan Hofer
Journal:  Mediators Inflamm       Date:  2015-02-11       Impact factor: 4.711

9.  Immune-Response Patterns and Next Generation Sequencing Diagnostics for the Detection of Mycoses in Patients with Septic Shock-Results of a Combined Clinical and Experimental Investigation.

Authors:  Sebastian O Decker; Annette Sigl; Christian Grumaz; Philip Stevens; Yevhen Vainshtein; Stefan Zimmermann; Markus A Weigand; Stefan Hofer; Kai Sohn; Thorsten Brenner
Journal:  Int J Mol Sci       Date:  2017-08-18       Impact factor: 5.923

10.  Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction.

Authors:  Stefan Hofer; Thorsten Brenner; Christian Bopp; Jochen Steppan; Christoph Lichtenstern; Jürgen Weitz; Thomas Bruckner; Eike Martin; Ursula Hoffmann; Markus A Weigand
Journal:  Crit Care       Date:  2009-06-18       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.